Mid‐Term Results of Dual‐Chamber Pacing in Children with Hypertrophic Obstructive Cardiomyopathy

Alday, Luis; Bruno, Eva; Moreyra, Eduardo; Amuchastegui, Luis M.; Juaneda, Ernesto; Maisuls, Hector

doi:10.1111/j.1540-8175.1998.tb00609.x

Cited by 5 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with obstructive hypertrophic cardiomyopathy still symptomatic despite medical treatment, we implanted DDD pacemakers as has already been reported. 31,32 Symptomatic improvement was achieved in all these patients, along with a significant reduction of the gradient across the left ventricular outflow tract. This made it possible to discontinue the medical treatment in all.…”

Section: Discussionmentioning

confidence: 89%

Clinical features of hypertrophic cardiomyopathy in the young

et al. 2002

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 89%

Clinical features of hypertrophic cardiomyopathy in the young

et al. 2002

Self Cite

View full text Add to dashboard Cite

show abstract

“…Small case series in symptomatic children with outflow obstruction noted symptomatic improvement, reduced outflow obstruction, reduced left ventricular hypertrophy, and improved exercise tolerance [34][35][36]. In contrast to early studies [37], later controlled studies found that only about 60% of subjects improved and in the majority of those who benefited, the response was documented to be due to placebo effect and an adverse effect on symptoms was seen in 5% [38].…”

Section: Pacemaker Therapymentioning

confidence: 94%

Treatment of hypertrophic cardiomyopathy in childhood

Colan

2011

Progress in Pediatric Cardiology

View full text Add to dashboard Cite

“…Results in small cohorts of children with outflow obstruction who were symptomatic despite medical therapy noted symptomatic improvement, reduced outflow obstruction, reduced left ventricular hypertrophy, and improved exercise tolerance 38–40. Despite early studies 41, subsequent controlled studies found that only about 60% of subjects improved.…”

Section: Familial Hypertrophic Cardiomyopathymentioning

confidence: 99%

Hypertrophic Cardiomyopathy in Childhood

Colan

2010

Heart Failure Clinics

View full text Add to dashboard Cite

Keywordscardiomyopathy; hypertrophic cardiomyopathy; sudden death; pediatrics; children; infants Hypertrophic cardiomyopathy (HCM) is defined as the presence of a hypertrophied, nondilated ventricle in the absence of another disease that creates a hemodynamic disturbance that is capable of producing the existent magnitude of wall thickening (eg, hypertension, aortic valve stenosis, catecholamine secreting tumors, hyperthyroidism, etc). HCM accounts for 42% of childhood cardiomyopathy and has an incidence of 0.47/100,000 children 1 and represents a heterogeneous group of disorders with a diversity that is more apparent in childhood than at any other age. It is possible to further subdivide these diseases based on a number of characteristics. A classification is presented in List 1 based on groupings of familial, syndromic, neuromuscular, and metabolic (storage disease and mitochondrial disorders). Other classification schemes are commonly used, including division into primary and secondary forms, where the primary form is a familial disorder ("familial hypertrophic cardiomyopathy", FHC) typically devoid of findings outside of the heart, and the secondary forms include diseases such as Friedreich ataxia 2 where ventricular hypertrophy is common but is not the dominant clinical manifestation and others, such as glycogenosis Type IX 3 , in which a systemic disorder has primarily or exclusively cardiac manifestations.Most of the available information for HCM derives from studies in adult populations, and the implication of these observations for pediatric populations is often uncertain. The purpose of this review is not to attempt to review the vast body of literature that has accumulated about HCM but rather to summarize key findings and to discuss their implications for diagnosis and management of children with HCM. Epidemiology and SurvivalThe Pediatric Cardiomyopathy Registry is a multicenter observational study of pediatric cardiomyopathies initiated in 1995 that in 2003 reported the sex, age, and race-specific incidence of the several forms of cardiomyopathy based on 2 geographically diverse sections of the United States 1 . Of note, the incidence of HCM was found to be 69% more common in males, occurred at 10 times the rate in subjects under age 1, and was significantly more common in blacks than in whites or Hispanics. Subsequently, the distribution of etiologies and the etiology-specific survival in 849 children, the largest series to date, was reported 4 . Overall, Corresponding author for proof and reprints: Steven D. Colan, M.D., Department of Cardiology, Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, (617) 355-7893, (617) 739-6282 (fax), colan@alum.mit.edu (email). Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable fo...

show abstract

Mid‐Term Results of Dual‐Chamber Pacing in Children with Hypertrophic Obstructive Cardiomyopathy

Cited by 5 publications

References 21 publications

Clinical features of hypertrophic cardiomyopathy in the young

Clinical features of hypertrophic cardiomyopathy in the young

Treatment of hypertrophic cardiomyopathy in childhood

Hypertrophic Cardiomyopathy in Childhood

Contact Info

Product

Resources

About